New York State Teachers Retirement System Has $127.59 Million Stock Holdings in Pfizer Inc. (NYSE:PFE)

New York State Teachers Retirement System reduced its position in shares of Pfizer Inc. (NYSE:PFE - Free Report) by 4.1% during the 4th quarter, according to the company in its most recent 13F filing with the Securities & Exchange Commission. The firm owned 4,809,274 shares of the biopharmaceutical company's stock after selling 207,222 shares during the quarter. New York State Teachers Retirement System owned 0.08% of Pfizer worth $127,590,000 at the end of the most recent quarter.

Other hedge funds also recently modified their holdings of the company. Wells Trecaso Financial Group LLC grew its stake in Pfizer by 2.5% in the third quarter. Wells Trecaso Financial Group LLC now owns 14,361 shares of the biopharmaceutical company's stock valued at $416,000 after acquiring an additional 350 shares during the period. Washington Trust Advisors Inc. lifted its holdings in shares of Pfizer by 0.7% during the 3rd quarter. Washington Trust Advisors Inc. now owns 49,216 shares of the biopharmaceutical company's stock valued at $1,424,000 after purchasing an additional 360 shares in the last quarter. PSI Advisors LLC grew its position in shares of Pfizer by 1.4% in the 4th quarter. PSI Advisors LLC now owns 27,823 shares of the biopharmaceutical company's stock valued at $738,000 after purchasing an additional 385 shares during the period. Western Pacific Wealth Management LP increased its stake in Pfizer by 10.5% during the 3rd quarter. Western Pacific Wealth Management LP now owns 4,073 shares of the biopharmaceutical company's stock worth $118,000 after purchasing an additional 386 shares in the last quarter. Finally, Waddell & Associates LLC raised its holdings in Pfizer by 1.6% during the 3rd quarter. Waddell & Associates LLC now owns 24,978 shares of the biopharmaceutical company's stock worth $723,000 after buying an additional 388 shares during the period. Hedge funds and other institutional investors own 68.36% of the company's stock.

Insider Buying and Selling at Pfizer

In related news, Director Ronald E. Blaylock purchased 19,457 shares of the stock in a transaction on Thursday, February 13th. The shares were purchased at an average cost of $25.65 per share, with a total value of $499,072.05. Following the acquisition, the director now directly owns 27,707 shares in the company, valued at $710,684.55. The trade was a 235.84 % increase in their ownership of the stock. The acquisition was disclosed in a document filed with the SEC, which is accessible through this link. Insiders own 0.06% of the company's stock.

Pfizer Stock Performance

NYSE PFE traded down $0.15 on Monday, hitting $25.50. 33,055,417 shares of the stock were exchanged, compared to its average volume of 37,577,760. The business's fifty day moving average is $26.28 and its 200 day moving average is $27.54. Pfizer Inc. has a 52 week low of $24.48 and a 52 week high of $31.54. The company has a market capitalization of $144.48 billion, a PE ratio of 18.08, a P/E/G ratio of 0.64 and a beta of 0.64. The company has a debt-to-equity ratio of 0.63, a current ratio of 1.00 and a quick ratio of 0.73.

Pfizer (NYSE:PFE - Get Free Report) last issued its earnings results on Tuesday, February 4th. The biopharmaceutical company reported $0.63 earnings per share (EPS) for the quarter, beating the consensus estimate of $0.48 by $0.15. The business had revenue of $17.76 billion during the quarter, compared to the consensus estimate of $17.26 billion. Pfizer had a net margin of 12.62% and a return on equity of 19.47%. Pfizer's revenue was up 24.7% on a year-over-year basis. During the same period last year, the business posted $0.10 EPS. Research analysts anticipate that Pfizer Inc. will post 2.95 EPS for the current fiscal year.

Pfizer Increases Dividend

The firm also recently declared a quarterly dividend, which will be paid on Friday, March 7th. Investors of record on Friday, January 24th will be paid a $0.43 dividend. This represents a $1.72 dividend on an annualized basis and a yield of 6.75%. The ex-dividend date is Friday, January 24th. This is a boost from Pfizer's previous quarterly dividend of $0.42. Pfizer's dividend payout ratio is 121.99%.

Analysts Set New Price Targets

PFE has been the subject of several research reports. Citigroup lowered their price objective on shares of Pfizer from $30.00 to $29.00 and set a "neutral" rating for the company in a research report on Tuesday, January 28th. UBS Group lowered their target price on Pfizer from $31.00 to $29.00 and set a "neutral" rating for the company in a report on Wednesday, January 8th. Guggenheim restated a "buy" rating and issued a $33.00 price target on shares of Pfizer in a report on Monday, February 10th. Cantor Fitzgerald reiterated an "overweight" rating and set a $45.00 price objective on shares of Pfizer in a report on Wednesday, October 23rd. Finally, StockNews.com cut Pfizer from a "strong-buy" rating to a "buy" rating in a research note on Wednesday, November 20th. One analyst has rated the stock with a sell rating, eight have assigned a hold rating, six have given a buy rating and two have given a strong buy rating to the stock. Based on data from MarketBeat, the stock presently has a consensus rating of "Moderate Buy" and an average target price of $31.92.

About Pfizer

Pfizer Inc discovers, develops, manufactures, markets, distributes, and sells biopharmaceutical products in the United States, Europe, and internationally. The company offers medicines and vaccines in various therapeutic areas, including cardiovascular metabolic, migraine, and women's health under the Eliquis, Nurtec ODT/Vydura, Zavzpret, and the Premarin family brands; infectious diseases with unmet medical needs under the Prevnar family, Abrysvo, Nimenrix, FSME/IMMUN-TicoVac, and Trumenba brands; and COVID-19 prevention and treatment, and potential future mRNA and antiviral products under the Comirnaty and Paxlovid brands.